Pharming Group N.V annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V R&D Spending Growth & History (PHAR)
Pharming Group N.V's r&d spending was $100.4M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $100.4M | $17.2M | +20.71% |
| 2024 | 2024-12-31 | $83.1M | $14.2M | +20.65% |
| 2023 | 2023-12-31 | $68.9M | $16.4M | +31.19% |
| 2022 | 2022-12-31 | $52.5M | −$17.8M | −25.35% |
| 2021 | 2021-12-31 | $70.4M | $31.9M | +82.69% |
| 2020 | 2020-12-31 | $38.5M | $6.7M | +21.18% |
| 2019 | 2019-12-31 | $31.8M | — | — |
Pharming Group N.V quarterly r&d spending
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $32.3M | $8.6M | +36.16% |
| Q1 2026 | 2026-03-31 | $25.6M | — | — |
| Q4 2025 | 2025-12-31 | $32.1M | — | — |
| Q3 2025 | 2025-09-30 | $23.4M | — | — |
| Q2 2025 | 2025-06-30 | $23.7M | — | — |
Pharming Group N.V r&d spending trends
Over the last five fiscal years, Pharming Group N.V's r&d spending increased from $38.5M to $100.4M, a change of $61.8M. The latest reported quarter, Q2 2026, shows $32.3M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...